Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Correspondence] Inhaled triple therapy in chronic obstructive pulmonary disease

Alberto Papi and colleagues1 reported that in 1532 patients with a history of exacerbation, triple therapy significantly reduced the exacerbation rate by 15% compared to double bronchodilation, without changing the individual patient risk of having at least one exacerbation. This statistical significance should be interpreted cautiously. Considering the relatively large difference in exacerbation rate and the large number of patients, a p value of 0·043 could be explained by differences in the distribution of exacerbations per patient.